Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis: Lian-Mei-Yin suppresses Yap1 to alleviates hepatic steatosis

• Published in: Acta biochimica et biophysica Sinica 2024-03, Vol.56 (4), p.621-633
• Main Authors: Zhang, Peiguang, Cao, Jieqiong, Liang, Xujing, Su, Zijian, Zhang, Bihui, Wang, Zhenyu, Xie, Junye, Chen, Gengrui, Chen, Xue, Zhang, Jinting, Feng, Yanxian, Xu, Qin, Song, Jianping, Hong, An, Chen, Xiaojia, Zhang, Yibo
• Format: Article
• Language: English
• ISSN: 1672-9145; 1745-7270
• DOI: 10.3724/abbs.2024025

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, with a global prevalence of 25%. Patients with NAFLD are more likely to suffer from advanced liver disease, cardiovascular disease, or type II diabetes. However, unfortunately, there is still a shortage of FDA-approved therapeutic agents for NAFLD. Lian-Mei-Yin (LMY) is a traditional Chinese medicine formula used for decades to treat liver disorders. It has recently been applied to type II diabetes which is closely related to insulin resistance. Given that NAFLD is another disease involved in insulin resistance, we hypothesize that LMY might be a promising formula for NAFLD therapy. Herein, we verify that the LMY formula effectively reduces hepatic steatosis in diet-induced zebrafish and NAFLD model mice in a time- and dose-dependent manner. Mechanistically, LMY suppresses Yap1-mediated Foxm1 activation, which is crucial for the occurrence and development of NAFLD. Consequently, lipogenesis is ameliorated by LMY administration. In summary, the LMY formula alleviates diet-induced NAFLD in zebrafish and mice by inhibiting Yap1/Foxm1 signaling-mediated NAFLD pathology.